Literature DB >> 3146324

Experience over 17 years with antioxidant treatment in Spielmeyer-Sjögren disease.

P Santavuori1, H Heiskala, T Westermarck, K Sainio, R Moren.   

Abstract

During the last 17 yr, 74 patients with Spielmeyer-Sjögren disease were treated in Finland with antioxidant supplementation. Twenty-seven patients received a combination of vitamin E, vitamin C, methionine and BHT. As the disease began to progress, the treatment was changed to a combination of sodium selenite and vitamin E in 14 of the 27 patients. The same combination was also given to 47 children (During the last 5-6 yr, vitamins B2 and B6 were also added.) who had not received previous antioxidant supplementation. The latter combination (called the Westermarck formula) appeared to be helpful to some patients. Statistical correlations between various neurological items and relevant laboratory data were sought. In the older patients a significant correlation was found between neurological dysfunction and ceruloplasmin, and also between epilepsy and ceruloplasmin, while a negative correlation was noticed between neurological dysfunction and glutathione peroxidase. In the younger patients, a negative correlation was observed between superoxide dismutase and epilepsy. Serum apolipoprotein B levels were below the normal range in the 6 patients investigated. So far the Westermarck formula seems to have been the best treatment devised yet in Spielmeyer-Sjögren disease, but further studies are needed for a better understanding of the pathogenesis of neuronal ceroid-lipofuscinoses disorders.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146324     DOI: 10.1002/ajmg.1320310629

Source DB:  PubMed          Journal:  Am J Med Genet Suppl        ISSN: 1040-3787


  10 in total

1.  Clinical trials in rare disease: challenges and opportunities.

Authors:  Erika F Augustine; Heather R Adams; Jonathan W Mink
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

2.  [18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.

Authors:  H M Ruottinen; J O Rinne; M Haaparanta; O Solin; J Bergman; V J Oikonen; I Järvelä; P Santavuori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

Review 3.  Physiological and nutritional importance of selenium.

Authors:  J Nève
Journal:  Experientia       Date:  1991-02-15

4.  Normal ascorbic acid in cerebrospinal fluid of patients with infantile neuronal ceroid-lipofuscinosis.

Authors:  J O Sass; D Skladal; M Brunner-Krainz
Journal:  Metab Brain Dis       Date:  1999-03       Impact factor: 3.584

5.  Spielmeyer-Vogt disease: clinical and neurophysiological aspects.

Authors:  L Piattella; C Cardinali; N Zamponi; O Papa
Journal:  Childs Nerv Syst       Date:  1991-08       Impact factor: 1.475

6.  MRI of neuronal ceroid lipofuscinosis. I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis.

Authors:  T Autti; R Raininko; S L Vanhanen; P Santavuori
Journal:  Neuroradiology       Date:  1996-07       Impact factor: 2.804

7.  Atypical juvenile neuronal ceroid lipofuscinosis: A report of three cases.

Authors:  Gururaj Setty; Rashid Saleem; Arif Khan; Nahin Hussain
Journal:  J Pediatr Neurosci       Date:  2013-05

Review 8.  Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights.

Authors:  John R Ostergaard
Journal:  Degener Neurol Neuromuscul Dis       Date:  2016-08-01

Review 9.  Application of Anticonvulsants, Antiepileptic Drugs, and Vitamin C in the Treatment and Analysis of Batten Disease.

Authors:  Shreya Reddy; Hetal Brahmbhatt
Journal:  Cureus       Date:  2022-01-30

10.  Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis.

Authors:  Katja M Kanninen; Alexandra Grubman; Jodi Meyerowitz; Clare Duncan; Jiang-Li Tan; Sarah J Parker; Peter J Crouch; Brett M Paterson; James L Hickey; Paul S Donnelly; Irene Volitakis; Imke Tammen; David N Palmer; Anthony R White
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.